Alveolar Dead Space as Predictor of Organ Failure in Severe Sepsis

Recruiting

• Conditions: Multi-organ Failure; Sepsis; Severe Sepsis; Septic Shock

• Registration Number: NCT01315782
• Lead Sponsor: The University of Texas Health Science Center, Houston

Brief Summary

This is an observational study to understand the changes in alveolar dead space in medical critically ill patients with severe infection (severe sepsis) requiring mechanical ventilation and the possibility to predict multi-organ failure.

The measurement of alveolar dead space used to require sophisticated equipment and time. New ventilators have microprocessors that allow rapid mathematical calculation with minimal intervention.

Detailed Description

The patient will be followed during their ICU stay up to two weeks while on mechanical ventilation.

Patient will be followed daily for the initial 48 hours and then once per week for 2 weeks while mechanically ventilated.

Study Timeline

• Study First Submitted: 2011-03-08
• Study First Submitted QC: 2011-03-14
• Study First Posted: 2011-03-15
• Study Start: 2016-12
• Status Verified: 2023-10
• Last Update Submitted: 2023-10-14
• Last Update Posted: 2023-10-17
• Primary Completion: 2024-12
• Study Completion: 2024-12

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Adults with severe sepsis or septic shock on mechanical ventilation
• Enrolled in the initial six hours of ICU admission

Exclusion Criteria

• Patients with withdrawal or hospice order.
• Patients with terminal, irreversible disease, expect to decease in 48 hours from ICU admission.
• Patients with COPD.
• Patients transferred from outside ICU with ongoing sepsis management for more than six hours.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Multi-organ failure	daily for 48 hours then weekly for 2 weeks.	Multi-oran failure will be accessed by daily laboratory data, heart function by echocardiogram if available, urinary output, vitals and use of vasopressors.

Secondary Outcome Measures

Name	Time	Method
Mortality	ICU mortality	All the patient will be followed up to 28-days to determine survival.

Trial Locations

Locations (1)

Memorial Hermann Hospital; 🇺🇸 Houston, Texas, United States